FORT WORTH, Texas, June 26, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative ...
AUSTIN, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug ...
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (TFF), an early-stage biopharmaceutical company focused on developing and commercializing new inhalation drug products for the treatment of ...
FORT WORTH, Texas, March 07, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing ...
Statements made in this press release regarding matters that are not historical facts are “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...
6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety Extension Phase; 1 patient has been treated for over a year and 3 additional ...
TFF Pharmaceuticals and Catalent will collaborate to develop TFF's platform for manufacturing dry powder particles. TFF Pharmaceuticals, a clinical-stage biopharmaceutical company, and Catalent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results